A 12-Month Clinical Study of LA-2585 (45.0 MG): A New 6-Month Subcutaneous Delivery System for Leuprolide Acetate for the Treatment of Prostate Cancer - Concepedia

Concepedia

Publication | Closed Access

A 12-Month Clinical Study of LA-2585 (45.0 MG): A New 6-Month Subcutaneous Delivery System for Leuprolide Acetate for the Treatment of Prostate Cancer

98

Citations

18

References

2006

Year

E. David Crawford, Oliver Sartor, Franklin Chu, Ramón Pérez, Gary Karlin, J. Garrett

The Journal of Urology

Abstract

LA-2585 (45.0 mg depot) consistently produced and maintained safe and effective serum testosterone suppression with total serum testosterone well below the medical castrate level of less than 50 ng/dl.

References

	Year	Citations

Page 1